Quantum Return Probability for Substitution Potentials

We propose an effective exponent ruling the algebraic decay of the average quantum return probability for discrete Schrodinger operators. We compute it for some non-periodic substitution potentials with different degrees of randomness, and do not find a complete qualitative agreement with the spectral type of the substitution sequences themselves, i.e., more random the sequence smaller such exponent.Comment: Latex, 13 pages, 6 figures; to be published in Journal of Physics

Extended states in 1D lattices: application to quasiperiodic copper-mean chain

The question of the conditions under which 1D systems support extended electronic eigenstates is addressed in a very general context. Using real space renormalisation group arguments we discuss the precise criteria for determining the entire spertrum of extended eigenstates and the corresponding eigenfunctions in disordered as well as quasiperiodic systems. For purposes of illustration we calculate a few selected eigenvalues and the corresponding extended eigenfunctions for the quasiperiodic copper-mean chain. So far, for the infinite copper-mean chain, only a single energy has been numerically shown to support an extended eigenstate [ You et al. (1991)] : we show analytically that there is in fact an infinite number of extended eigenstates in this lattice which form fragmented minibands.Comment: 10 pages + 2 figures available on request; LaTeX version 2.0

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)